Format

Send to

Choose Destination
Nanomedicine (Lond). 2019 Apr;14(7):851-870. doi: 10.2217/nnm-2018-0306. Epub 2019 Mar 22.

Gold nanoparticles for sustained antileukemia drug release: development, optimization and evaluation by quality-by-design approach.

Author information

1
Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India.

Abstract

AIM:

To design, develop, optimize and evaluate sustained-release dasatinib-loaded gold nanoparticles (DSB-GNPs) to treat chronic myeloid leukemia (CML) by using quality by design.

MATERIALS & METHODS:

In this study, we performed risk assessment, optimization, in vitro characterizations, stability study, drug release studies, cytotoxicity study and in vivo pharmacokinetic evaluation.

RESULTS:

DSB-GNPs of desired size, entrapment, smooth, spherical, stable and sustained drug release for 48 h were achieved. DSB-GNPs exhibited significantly more percentage growth inhibition and enhanced systemic bioavailability compared with pure DSB.

CONCLUSION:

The in vitro and in vivo evaluation exhibited that the DSB-GNPs have a potential cytotoxic effect, systemic bioavailability and sustained release making them a promising system of DSB delivery in the treatment of chronic myeloid leukemia.

KEYWORDS:

chronic myeloid leukemia; cytotoxicity study; dasatinib; full factorial design; gold nanoparticles; quality by design; risk assessment

PMID:
30901283
DOI:
10.2217/nnm-2018-0306
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center